Why the study?
Does 17beta-estradiol alter atrial refractoriness and the risk of cisapride-induced ventricular arrhythmia in a canine model?
Population
Dogs (n=30 in experiment 1; n=23 in experiment 2)
Comparison
17beta-estradiol pretreatment vs No pretreatment (control group) or cisapride only
Design
Preclinical
Follow-up
Acute (during experiment)
Authors
Loading...
Preclinical data flag potential estrogen-cisapride proarrhythmic interaction; leaves open human relevance pending clinical studies.
Does 17beta-estradiol alter atrial refractoriness and the risk of cisapride-induced ventricular arrhythmia in a canine model?
17beta-estradiol attenuates pacing-induced shortening of atrial refractoriness but significantly increases the risk of cisapride-induced torsades de pointes in a canine model.
Chen et al. (1999) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: